Passage Bio (PASG) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

PASG · Stock Price

USD 4.08-2.50 (-37.99%)

Market Cap: $13.0M

Historical price data

Market Cap: $13.0MPipeline: 1 drugFounded: 2017Employees: 51-200HQ: Philadelphia, United States

Sector Ranking#85 in Cell & Gene Therapy #86 in Neuroscience & CNS

Overview

Passage Bio is a clinical-stage biotech focused on developing AAV-based gene therapies for rare, monogenic CNS disorders. The company's mission is to deliver one-time, transformative treatments that permanently redefine the course of neurodegenerative diseases. Its strategy centers on two lead Phase 1/2 programs—PBFT02 for FTD-GRN and PBGM01 for GM1 gangliosidosis—supported by a technology platform emphasizing optimized delivery and manufacturing. Despite significant clinical and financial challenges common to the gene therapy sector, Passage Bio represents a focused, platform-driven approach to treating devastating neurological conditions.

NeurologyRare Diseases

Technology Platform

Engineered adeno-associated virus (AAV) vector-based gene therapy platform focused on optimized capsids and intracisternal magna (ICM) delivery for broad distribution of therapeutic genes in the central nervous system.

Pipeline

1

1 drug in pipeline

Drug	Indication	Stage	Watch
PBFT02	Frontotemporal Dementia	Phase 1/2

Opportunities

Success in its lead programs for FTD-GRN and GM1 gangliosidosis could unlock multi-billion dollar markets in high-unmet-need, monogenic CNS disorders.

Validating its intracisternal magna (ICM) delivery platform would create significant optionality value for applying the same approach to other neurological diseases in its pipeline.

Risk Factors

The company faces high clinical development risk with its lead Phase 1/2 programs, significant future dilution risk given its pre-revenue status and need for additional capital, and commercialization challenges inherent in ultra-rare disease markets.

The entire platform is unproven in late-stage trials.

Competitive Landscape

Passage Bio competes in the crowded CNS gene therapy space against both large pharma and biotech peers. In FTD-GRN, competitors include other gene therapy (e.g., Prevail/Eli Lilly) and antisense oligonucleotide approaches. In GM1, it faces Lysogene and others, with differentiation hinging on safety, efficacy, and delivery method.